Back to Newsroom

Pulmatrix to Highlight PUR1900 Data at 2015 North American Cystic Fibrosis Conference

LEXINGTON, Mass., Sept. 11, 2015 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data regarding the pharmacokinetics and potency of PUR1900, the first inhaled antifungal medication for cystic fibrosis, will be presented at the 2015 North American Cystic Fibrosis Conference. Pulmatrix’s chief scientific officer, David L. Hava, Ph.D., will present the data, which show that itraconazole, the drug selected for development as PUR1900, was active and potent in vitro against Aspergillus fumigatus, a pathogen causing pulmonary infection in cystic fibrosis. Pharmacokinetic data also demonstrate that PUR1900 achieved high lung concentrations of itraconazole and low systemic exposure following lung delivery in rats, highlighting the advantages of pulmonary delivery for this compound.

Click here to read more